AR054417A1 - Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas. - Google Patents
Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas.Info
- Publication number
- AR054417A1 AR054417A1 ARP050105432A ARP050105432A AR054417A1 AR 054417 A1 AR054417 A1 AR 054417A1 AR P050105432 A ARP050105432 A AR P050105432A AR P050105432 A ARP050105432 A AR P050105432A AR 054417 A1 AR054417 A1 AR 054417A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- groups
- alkyl
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Procesos para la preparacion de tales compuestos, su uso en el tratamiento de la obesidad, trastornos psiquiátricos y neurologicos, y a composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de formula (1) y sales aceptables para uso farmacéutico del mismo, en las cuales R1 representa a) un grupo alcoxi C1-6 sustituido por uno o más grupos fluoro o b) un grupo de formula fenil (CH2)pO- donde p es 1, 2 o 3 y el anillo fenilo está sustituido opcionalmente por 1,2 o 3 grupos representados por Z, c) un grupo R5S(O)2s en el cual R5 representa un grupo alquilo C1-6 sustituido opcionalmente por uno o más grupos fluoro, o R5 representa un grupo fenilo o heteroarilo, cada uno de los cuales está sustituido opcionalmente por 1, 2 o 3 grupos representados por Z o d) un grupo de formula (R6)3Si en la cual R6 representa un grupo alquilo C1-6 el cual puede ser igual o diferente; Ra representa halo, un grupo alquilo C1-3 o un grupo alcoxi C1-3; m es 0, 1 2 o 3; R2 representa un grupo alquilo C1-3, un grupo alcoxi C1-3, hidroxi, nitro, ciano o halo; n es 0, 1 2 o 3K R3 representa a) un grupo S-Y-NR7R8 en el cual X es CO o SO2, Y está ausente o representa NH sustituido opcionalmente por un grupo alquilo C-3; t R7 t R8 representan independientemente: un grupo alquilo C1-6 sustituido opcionalmente por 1, 2 o 3 grupos representados por W; un grupo cicloalquilo C3-15 sustituido opcionalmente por 1, 2 o 3 grupos representados W; un grupo -(CH2)r(fenil)s en el cual r es 0, 1, 2, 3 o 4, s es 1 cuando r es 0, de lo contrario s es 1 o 2 y los grupos fenilo están opcional e independientemente sustituidos por uno, dos o tres grupos representados por Z; un grupo heterocíclico saturado de 5 a 8 miembros que contiene un nitrogeno y opcionalmente uno de los siguientes: oxígeno, azufre o un nitrogeno adicional donde el grupo heterocíclico está sustituido opcionalmente por uno o más grupos alquilo C1-3, hidroxi o bencilo; un grupo -(CH2)tHet en el cual t es 0, 1,2, 3 o 4 y la cadena de alquileno está opcionalmente sustituida por uno o más grupos alquilo C1-3 y Het representa un grupo heteroarilo sustituido opcionalmente por uno, dos o tres grupos seleccionados entre el grupo alquilo C1-5 un grupo alcoxi C1-5 o halo; o R7 y R8 junto con el átomo de nitrogeno al cual están unidos representan un grupo heterocíclico de 5 a 8 miembros saturado o parcialmente insaturado que contiene un nitrogeno u opcionalmente uno de los siguientes: oxígeno, azufre o un nitrogeno adicional; donde el grupo heterocíclico está sustituido opcionalmente por uno o más grupos alquilo C1-3, hidroxi, fluoro o bencilo; o b) oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, pirrolilo, pirazolilo, imidazolilo, triazolilo, tetrazolilo, tienilo, furilo u oxazolinilo, cada uno sustituido opcionalmente por 1,2 o 3 grupos Z; R4 representa un grupo alquilo C1-6 sustituido por uno o más de los siguientes: hidroxi, un grupo NReRf en el cual Re y Rf representan independientemente H, un grupo alquilo C1-6 sustituido opcionalmente por uno o más grupos hidroxi o uno o más grupos alcoxi C1-6 o Re y Rf junto en el nitrogeno al cual están unidos representan un anillo heterocíclico saturado de 4 a 7 miembros que contiene opcionalmente un oxígeno o un segundo nitrogeno, donde dicho anillo está sustituido opcionalmente por uno o más de los siguientes grupos: hidroxi, fluoro o alquilo C1-6; Z representa un grupo alquilo C1-3, un grupo alcoxi C1-3, hidroxi, halo, trifluormetilo, trifluorometiltio, difluorometoxi, trifluorometoxi, trifluorometilsulfonilo, nitro, amino, mono o dialquilamino C1-3- carbamoílo y acetilo; y W representa carboxi, un grupo alcoxi C1-3 carbonilo, hidroxi, fluoro, un grupo alquilo C1-3, un grupo alcoxi C1-3, amino, mono o dialquilamino C1-3, o una amina heterocíclica seleccionada entre morfolinilo, pirrolidinilo, peperdinilo o peperazinilo donde la amina heterocíclica está opcionalmente sustituida por un grupo alquilo C1-3 o hidroxi
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0428073A GB0428073D0 (en) | 2004-12-23 | 2004-12-23 | Therapeutic agents |
GB0514348A GB0514348D0 (en) | 2005-07-13 | 2005-07-13 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054417A1 true AR054417A1 (es) | 2007-06-27 |
Family
ID=35911182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105432A AR054417A1 (es) | 2004-12-23 | 2005-12-21 | Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas. |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080319019A1 (es) |
EP (1) | EP1833802A2 (es) |
JP (1) | JP2008525401A (es) |
AR (1) | AR054417A1 (es) |
TW (1) | TW200633986A (es) |
WO (1) | WO2006067428A2 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008526887A (ja) * | 2005-01-10 | 2008-07-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なヘテロピロール類似体 |
GB0518817D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
EP1772449A1 (en) * | 2005-10-05 | 2007-04-11 | Bayer CropScience S.A. | New N-alkyl-heterocyclyl carboxamide derivatives |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
EP1735287A1 (en) * | 2004-04-03 | 2006-12-27 | Astrazeneca AB | Therapeutic agents |
-
2005
- 2005-12-21 JP JP2007547631A patent/JP2008525401A/ja not_active Withdrawn
- 2005-12-21 AR ARP050105432A patent/AR054417A1/es not_active Application Discontinuation
- 2005-12-21 US US11/793,375 patent/US20080319019A1/en not_active Abandoned
- 2005-12-21 WO PCT/GB2005/004956 patent/WO2006067428A2/en active Application Filing
- 2005-12-21 EP EP05821390A patent/EP1833802A2/en not_active Withdrawn
- 2005-12-23 TW TW094146048A patent/TW200633986A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006067428A2 (en) | 2006-06-29 |
WO2006067428A3 (en) | 2007-12-06 |
EP1833802A2 (en) | 2007-09-19 |
TW200633986A (en) | 2006-10-01 |
JP2008525401A (ja) | 2008-07-17 |
US20080319019A1 (en) | 2008-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054417A1 (es) | Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas. | |
AR054184A1 (es) | Derivados de 1,5 difenilpirazol. procesos de obtencion y composiciones farmaceuticas. | |
AR047683A1 (es) | Pirazoles para el tratamiento de obesidad y trastornos psiquiatricos | |
AR049487A1 (es) | Compuestos de imidazol sustituidos | |
AR042658A1 (es) | Derivados de 1,5-diaril-pirrol-3-carboxamida y su uso como moduladores de receptores canabinoides | |
RS52061B (en) | PIRAZOLYL-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | |
NO20050741L (no) | Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den | |
PE20090048A1 (es) | Derivados de glicina n-sustituidos: inhibidores de prolil hidroxilasa | |
RS50755B (sr) | Supstituisani aril i heteroaril derivati kao modulatori metabolizma i profilakse i lečenje poremećaja proisteklih iz toga | |
AR051293A1 (es) | Inhibidores bace | |
AR041250A1 (es) | Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa | |
AR042659A1 (es) | Derivados de 4-5 diariltiazoles como ligandos de cb-1 | |
AR046758A1 (es) | Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
EA200900066A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
AR063643A1 (es) | Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas | |
CO5590917A2 (es) | Derivados de 5,6-diaril-pirazina-2-amida como antagonistas cb1 | |
EA200700192A1 (ru) | Производные фталазина в качестве ингибиторов parp | |
CO5690599A2 (es) | Derivados de 3-(4-aminofenil) tienopirimid-4-ona como antagonistas mch r1 para el tratamiento de obesidad, diabetes, depresion y ansiedad | |
AR063625A1 (es) | COMPUESTOS HETEROCICLICOS eTILES COMO AGENTES ANTICANCEROSOS | |
CY1111707T1 (el) | Παραγωγα toy 1,4 διαζαδικυκλο 3.2.1 οκτανοκαρβοξυαμιδιου, η παρασκευη τους και η θεραπευτικη εφαρμογη τους | |
AR055368A1 (es) | Derivados de pirazol, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades neurodegenerativas y la obesidad | |
EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
EA200602136A1 (ru) | Комбинации замещенных 1-фенил-1,5-дигидропиридо[3,2-b] индол-2-онов и других ингибиторов вич | |
MX2011007864A (es) | Isosteros para realzar la transcripcion y su uso en terapia. | |
AR044830A1 (es) | Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |